Table 4.
Effect of montelukast versus fluticasone on pulmonary function and airway inflammatory biomarkers in wheezy phenotype group (G3).
| G3A | G3B | P | |||||
|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | Percentage change | Before treatment | After treatment | Percentage change | ||
| FEV1% predicted | 69.2 ± 1.8 | 75.2 ± 2.1* | 8.6% | 70.2 ± 1.1 | 80.1 ± 0.9* | 14.1% | <0.001 |
| Total sIgE (IU/mL) | 182.2 ± 13.2 | 175.1 ± 11.2 | 3.89% | 184.8 ± 11.8 | 165.8 ± 9.8 | 10.28% | 0.9 |
| Peripheral eosinophilic% | 7.4 ± 0.9 | 4.2 ± 0.19* | −43.24% | 6.9 ± 0.8 | 2.8 ± 0.2* | −59.42% | <0.001 |
| sECP (μg/L) | 50.2 ± 7.1 | 32.3 ± 6.2* | −35.65% | 47.8 ± 7.1 | 22.9 ± 4.3* | −52.09% | <0.001 |
| sICAM-1 (ng/mL) | 701.9 ± 59.2 | 692 ± 63.2 | 1.41% | 708 ± 60.1 | 680 ± 50.2 | 3.95% | 0.8 |
| sVCAM-1 (ng/mL) | 860.2 ± 219.8 | 823 ± 198.2 | 4.32% | 866.9 ± 230.9 | 811 ± 180.9 | 6.44% | 0.78 |
| sIL-2R (pg/mL) | 3428 ± 329.2 | 3411 ± 230.1 | 0.49% | 3439 ± 330.2 | 3400 ± 310.1 | 1.13% | 0.86 |
G3A: wheezy group treated with montelukast. G3B: wheezy group treated with fluticasone.
Data are expressed as mean (SD). *P < 0.05 is significant (for each group before and after treatment).
Mann-Whitney U-test was used to compare both groups.